Furosemide
NDC Package 59923-607-04
Package Information
Furosemide is parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Marketed by Areva Pharmaceuticals, this product is identified by NDC 59923-607 and is authorized under FDA application ANDA208435.
Identification & Billing
- RxCUI: 1719286 - furosemide 100 MG in 10 ML Injection
- RxCUI: 1719286 - 10 ML furosemide 10 MG/ML Injection
- RxCUI: 1719286 - furosemide 100 MG per 10 ML Injection
- RxCUI: 1719291 - furosemide 40 MG in 4 ML Injection
- RxCUI: 1719291 - 4 ML furosemide 10 MG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59923 - Areva Pharmaceuticals
- 59923-607 - Furosemide
- 59923-607-04 - 25 VIAL in 1 CARTON / 4 mL in 1 VIAL (59923-607-01)
- 59923-607 - Furosemide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59923-607-04 identifies a specific commercial package of 25 vial in 1 carton / 4 ml in 1 vial (59923-607-01) of Furosemide, labeled by Areva Pharmaceuticals. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Areva Pharmaceuticals on January 01, 2025. The current certification is valid through December 31, 2021.
How is this Areva Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59923060704. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.